Large-cap Health Care company Bristol-Myers Squibb Company has moved -0.6% so far today on a volume of 6,706,050, compared to its average of 10,885,673. In contrast, the S&P 500 index moved 1.0%.
Bristol-Myers Squibb Company trades -22.29% away from its average analyst target price of $72.4 per share. The 20 analysts following the stock have set target prices ranging from $55.0 to $90.0, and on average have given Bristol-Myers Squibb Company a rating of buy.
If you are considering an investment in BMY, you'll want to know the following:
-
Bristol-Myers Squibb Company's current price is 89.7% above its Graham number of $29.66, which implies that at its current valuation it does not offer a margin of safety
-
Bristol-Myers Squibb Company has moved -19.0% over the last year, and the S&P 500 logged a change of 23.0%
-
Based on its trailing earnings per share of 3.76, Bristol-Myers Squibb Company has a trailing 12 month Price to Earnings (P/E) ratio of 15.0 while the S&P 500 average is 15.97
-
BMY has a forward P/E ratio of 7.2 based on its forward 12 month price to earnings (EPS) of $7.81 per share
-
The company has a price to earnings growth (PEG) ratio of 3.16 — a number near or below 1 signifying that Bristol-Myers Squibb Company is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.68 compared to its sector average of 4.16
-
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
-
Based in New York, the company has 34,300 full time employees and a market cap of $117.54 Billion. Bristol-Myers Squibb Company currently returns an annual dividend yield of 4.0%.